U
UNIQURE NV
NASDAQ: QURE (uniQure N.V.)
Last update: 6 hours ago23.93
0.15 (0.63%)
| Previous Close | 23.78 |
| Open | 23.81 |
| Volume | 908,815 |
| Avg. Volume (3M) | 3,333,424 |
| Market Cap | 1,490,639,488 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 85.26 |
| Price / Book | 6.76 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | uniQure N.V. | Bearish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 4,444,444 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 3,988,971 |
| Aberdeen Group Plc | 30 Sep 2025 | 2,939,743 |
| Fred Alger Management, Llc | 30 Sep 2025 | 1,290,391 |
| Jennison Associates Llc | 30 Sep 2025 | 999,484 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 192.52%) | Buy |
| Median | 49.00 (104.76%) | |
| Low | 33.00 (Mizuho, 37.90%) | Buy |
| Average | 49.88 (108.44%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 26.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 11 Dec 2025 | 40.00 (67.15%) | Buy | 19.75 |
| Mizuho | 09 Dec 2025 | 33.00 (37.90%) | Buy | 20.78 |
| Chardan Capital | 04 Dec 2025 | 53.00 (121.48%) | Buy | 22.74 |
| 11 Nov 2025 | 53.00 (121.48%) | Buy | 30.84 | |
| Wells Fargo | 12 Nov 2025 | 60.00 (150.73%) | Buy | 30.12 |
| 02 Oct 2025 | 80.00 (234.31%) | Buy | 54.50 | |
| Leerink Partners | 10 Nov 2025 | 60.00 (150.73%) | Buy | 26.15 |
| Goldman Sachs | 04 Nov 2025 | 38.00 (58.80%) | Hold | 30.44 |
| HC Wainwright & Co. | 04 Nov 2025 | 70.00 (192.52%) | Buy | 30.44 |
| 06 Oct 2025 | 110.00 (359.67%) | Buy | 52.91 | |
| RBC Capital | 04 Nov 2025 | 45.00 (88.05%) | Buy | 30.44 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Dec 2025 | Announcement | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
| 10 Nov 2025 | Announcement | uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| 06 Nov 2025 | Announcement | uniQure to Announce Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |